Apex Biotechnology Corp.

Taiwan Stock Exchange 1733.TW

Apex Biotechnology Corp. Shareholders' Equity for the year ending December 31, 2023: USD 58.52 M

Apex Biotechnology Corp. Shareholders' Equity is USD 58.52 M for the year ending December 31, 2023, a -1.29% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Apex Biotechnology Corp. Shareholders' Equity for the year ending December 31, 2022 was USD 59.28 M, a -6.24% change year over year.
Apex Biotechnology Corp. Shareholders' Equity for the year ending December 31, 2021 was USD 63.23 M, a 8.09% change year over year.
Apex Biotechnology Corp. Shareholders' Equity for the year ending December 31, 2020 was USD 58.50 M, a 4.42% change year over year.
Apex Biotechnology Corp. Shareholders' Equity for the year ending December 31, 2019 was USD 56.02 M, a 4.34% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Taiwan Stock Exchange: 1733.TW

Apex Biotechnology Corp.

CEO	Dr. Thomas Y. S. Shen Ph.D.
IPO Date	June 14, 2000
Location	Taiwan
Headquarters	No. 7, Li-Hsin 5th Road
Employees	641
Sector	Healthcare
Industries Telehealth Biotechnology Cleaning Supplies Hardware & Electronics Medical Instruments Personal Care Pharmaceuticals Robotics

Description

Apex Biotechnology Corp. engages in the research, development, manufacture, and sale of home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing, and hemoglobin screening systems. It also provides pesticide residues check systems; and care management and tele-health services. The company was founded in 1997 and is headquartered in Hsinchu City, Taiwan.

Key trends

Past 5 years